Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CSL 346

Drug Profile

CSL 346

Alternative Names: 2H10; CSL-346

Latest Information Update: 02 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zenyth Therapeutics
  • Developer CSL; Zenyth Therapeutics
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Fatty acid modulators; Immunomodulators; Vascular endothelial growth factor B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic nephropathies; Type 2 diabetes mellitus
  • Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

  • 13 Nov 2017 Phase-I clinical trials in Type-2 diabetes mellitus and Diabetic nephropathies (In volunteers) in Australia (SC) (ACTRN12617001554358)
  • 10 Feb 2017 Preclinical trials in Diabetic nephropathies in Australia (SC) before February 2017 (9211410; CSL pipeline)
  • 10 Feb 2017 Preclinical data in mouse models released by CSL
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top